| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 95 | — | 17.8x | Top tier | |
Growth | 25 | 10.1% | 7.1% | Bottom tier | |
Quality | 72 | 2.5% | 4.5% | Top tier | |
Safety | 23 | 9.7x | 2.6x | Bottom tier | |
Capital Return | 95 | — | 2.12% | Top tier | |
Momentum | 49 | -13.8% | 2.9% | Around median | |
Sentiment | 39 | 4 | 3 | Bottom tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Bausch Health Companies Inc. operates through a diversified healthcare portfolio that includes Salix, International, Solta Medical, and Diversified, in addition to its economic interest in Bausch + Lomb. Salix relies heavily on Xifaxan, while International generates revenue from pharmaceutical portfolios across EMEA, LATAM, and Canada, and Solta Medical benefits from medical aesthetics products and Asia-Pacific markets. In the second quarter of fiscal 2026, Bausch Health revenue excluding Bausch + Lomb was approximately $1.458 billion, including $758 million from Salix, $305 million from International, $176 million from Solta Medical, and $219 million from Diversified.
On a consolidated basis, revenue for the second quarter of fiscal 2026 was approximately $2.852 billion, up 13% on a reported basis and 11% organically, and EDGAR data recorded net income of $258 million and earnings per share of $0.68. Adjusted gross margin was 72.9%, up 230 basis points, and adjusted earnings before interest, taxes, depreciation, and amortization reached $1.075 billion, up 28%, while adjusted cash flow from operations increased 44% to $637 million. Bausch Health excluding Bausch + Lomb recorded an adjusted earnings before interest, taxes, depreciation, and amortization margin of 59%, adjusted earnings of $865 million, and adjusted cash flow from operations of $471 million.
The figures reveal strong operating improvement offset by divergence in longer-term profitability; the company generated net income of $157 million and revenue of $10.3 billion in fiscal 2025, but the latest available trailing 12-month period in 2026 showed revenue of $10.9 billion and a net loss of $1.1 billion. Within the portfolio, Salix led growth with a 21% increase in revenue, while Solta Medical reported revenue rose 38% and segment profit increased 69%, whereas Diversified revenue remained flat at $219 million. Bausch + Lomb generated quarterly revenue of $1.394 billion, representing reported growth of 9%.
Automated analysis for informational purposes only — not investment advice.
The stock has a consensus Buy rating with an average target of $9.83, within a wide range of $8 to $16; the average is approximately 23% above the upper end of the 52-week range of $8, while the highest target is twice that level. No positive price-to-earnings multiple is available because of a net loss of $1.1 billion in the latest available trailing 12-month period in 2026, so the valuation depends heavily on continued operating improvement, debt reduction, and the assumption that Xifaxan exclusivity remains in place through January 1, 2028.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
Consolidated revenue reached $2.852 billion, up 13% on a reported basis and 11% organically. Adjusted earnings before interest, taxes, depreciation, and amortization increased 28% to $1.075 billion, while adjusted cash flow from operations rose 44% to $637 million. Xifaxan and Solta Medical were among the most prominent drivers, with Xifaxan revenue growing 26% and Solta Medical reported revenue growing 38%.
The Salix segment generated revenue of $758 million in the second quarter of fiscal 2026, representing approximately 52% of Bausch Health's $1.458 billion in revenue excluding Bausch + Lomb. Xifaxan revenue increased 26%, and the drug was the largest driver of Salix's 21% growth. The fiscal 2027 adjusted earnings outlook of $2.7 billion assumes continued Xifaxan exclusivity through January 1, 2028, while intellectual property litigation remains an unresolved factor.
The company reduced net debt by $434 million during the second quarter of fiscal 2026 to $13.7 billion. This was supported by adjusted cash flow from operations of $471 million and adjusted free cash flow of $465 million at Bausch Health excluding Bausch + Lomb. Despite this improvement, news on August 12, 2026 indicated long-term debt of $15 billion and significant credit risk, making capital structure repair a stated priority.
Solta Medical recorded revenue of $176 million in the second quarter of fiscal 2026, up 38% on a reported basis, while segment profit reached $91 million after growing 69%. Revenue in China increased 136% following the consolidation of full-service distributor Shibo, while Taiwan grew 42% and South Korea grew 8%. Management estimated full-year segment profit at approximately $330 million, nearly $100 million above the fiscal 2025 level.
The company, excluding Bausch + Lomb, expects revenue of between $5.35 billion and $5.50 billion and adjusted earnings before interest, taxes, depreciation, and amortization of between $3.025 billion and $3.100 billion in fiscal 2026. It also expects adjusted cash flow from operations of between $1.4 billion and $1.475 billion. Conversely, management identified negative second-half impacts including approximately $150 million from rebate and inventory adjustments, $50 million from generic competition for Aplenzin, and approximately $75 million from revenue erosion in the Medicaid and 340B channels.
